Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Farde

Showing results (41-50 of 218) with videos related to

Pageof 22
Sort By:
Peerj|November 28, 2018
Serotonin 5-HT<sub>1A</sub> receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testingGina Griffioen, Granville J Matheson, Simon Cervenka, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 6, 2013
Test-retest reliability of [11C]AZ10419369 binding to 5-HT(1B) receptors in human brainMagdalena Nord, Sjoerd J Finnema, Martin Schain, et al.
The International Journal of Neuropsychopharmacology|April 9, 2019
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis PatientsPer Stenkrona, Granville J Matheson, Christer Halldin, et al.
Psychopharmacology|July 11, 2002
Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindoleSvante Nyberg, Hans Olsson, Ulrika Nilsson, et al.
Translational Psychiatry|July 18, 2018
Serotonin concentration enhancers at clinically relevant doses reduce [<sup>11</sup>C]AZ10419369 binding to the 5-HT<sub>1B</sub> receptors in the nonhuman primate brainKai-Chun Yang, Akihiro Takano, Christer Halldin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2018
Nigrostriatal dopamine transporter availability in early Parkinson's diseasePatrik Fazio, Per Svenningsson, Zsolt Cselényi, et al.
Nuclear Medicine and Biology|January 29, 2013
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primateMagnus Schou, Katarina Varnäs, Aurelija Jucaite, et al.
The International Journal of Neuropsychopharmacology|April 12, 2011
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjectsMagdalena Nord, Svante Nyberg, Jacob Brogren, et al.
Neuroinformatics|June 2, 2014
Evaluation of two automated methods for PET region of interest analysisMartin Schain, Katarina Varnäs, Zsolt Cselényi, et al.
Psychopharmacology|May 19, 2015
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET studySjoerd J Finnema, Christer Halldin, Benny Bang-Andersen, et al.
Pageof 22

Showing results (41-50 of 218) with videos related to

Sort By:
Pageof 22
Peerj|November 28, 2018
Serotonin 5-HT<sub>1A</sub> receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testingGina Griffioen, Granville J Matheson, Simon Cervenka, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 6, 2013
Test-retest reliability of [11C]AZ10419369 binding to 5-HT(1B) receptors in human brainMagdalena Nord, Sjoerd J Finnema, Martin Schain, et al.
The International Journal of Neuropsychopharmacology|April 9, 2019
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis PatientsPer Stenkrona, Granville J Matheson, Christer Halldin, et al.
Psychopharmacology|July 11, 2002
Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindoleSvante Nyberg, Hans Olsson, Ulrika Nilsson, et al.
Translational Psychiatry|July 18, 2018
Serotonin concentration enhancers at clinically relevant doses reduce [<sup>11</sup>C]AZ10419369 binding to the 5-HT<sub>1B</sub> receptors in the nonhuman primate brainKai-Chun Yang, Akihiro Takano, Christer Halldin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2018
Nigrostriatal dopamine transporter availability in early Parkinson's diseasePatrik Fazio, Per Svenningsson, Zsolt Cselényi, et al.
Nuclear Medicine and Biology|January 29, 2013
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primateMagnus Schou, Katarina Varnäs, Aurelija Jucaite, et al.
The International Journal of Neuropsychopharmacology|April 12, 2011
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjectsMagdalena Nord, Svante Nyberg, Jacob Brogren, et al.
Neuroinformatics|June 2, 2014
Evaluation of two automated methods for PET region of interest analysisMartin Schain, Katarina Varnäs, Zsolt Cselényi, et al.
Psychopharmacology|May 19, 2015
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET studySjoerd J Finnema, Christer Halldin, Benny Bang-Andersen, et al.
Pageof 22